• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

COVID-19: The Uninvited Guest in the Intensive Care Unit - Implications for Pharmacotherapy.

作者信息

Stringer Kathleen A, Puskarich Michael A, Kenes Michael T, Dickson Robert P

机构信息

Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, Michigan.

Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, School of Medicine, University of Michigan, Ann Arbor, Michigan.

出版信息

Pharmacotherapy. 2020 May;40(5):382-386. doi: 10.1002/phar.2394. Epub 2020 May 4.

DOI:10.1002/phar.2394
PMID:32267979
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7262068/
Abstract
摘要

相似文献

1
COVID-19: The Uninvited Guest in the Intensive Care Unit - Implications for Pharmacotherapy.新型冠状病毒肺炎：重症监护病房中的不速之客——对药物治疗的影响
Pharmacotherapy. 2020 May;40(5):382-386. doi: 10.1002/phar.2394. Epub 2020 May 4.
2
Curing COVID-19.治愈新冠病毒肺炎
Lancet Infect Dis. 2020 Oct;20(10):1101. doi: 10.1016/S1473-3099(20)30706-4. Epub 2020 Sep 10.
3
Race to find COVID-19 treatments accelerates.寻找新冠病毒治疗方法的竞赛加速。
Science. 2020 Mar 27;367(6485):1412-1413. doi: 10.1126/science.367.6485.1412.
4
Puzzle of highly pathogenic human coronaviruses (2019-nCoV).高致病性人类冠状病毒（2019新型冠状病毒）之谜。
Protein Cell. 2020 Apr;11(4):235-238. doi: 10.1007/s13238-020-00693-y.
5
COVID-19: Stay Cool toward Corticosteroids.新冠疫情：对皮质类固醇保持冷静态度。
Keio J Med. 2020 Jun 25;69(2):27-29. doi: 10.2302/kjm.2020-0007-LE. Epub 2020 May 30.
6
Favipiravir, an antiviral for COVID-19?法匹拉韦，一种用于治疗新冠肺炎的抗病毒药物？
J Antimicrob Chemother. 2020 Jul 1;75(7):2013-2014. doi: 10.1093/jac/dkaa171.
7
World War against COVID-19: How strong is our armamentarium?抗击新冠疫情之战：我们的武器库有多强大？
Med J Malaysia. 2020 May;75(3):314-315.
8
COVID-19 outbreak: the gold rush and the responsibilities of the scientific community.新冠疫情：淘金热与科学界的责任
Clin Microbiol Infect. 2020 Sep;26(9):1123-1124. doi: 10.1016/j.cmi.2020.05.002. Epub 2020 May 15.
9
COVID-19: Small-Molecule Clinical Trials Landscape.新冠病毒病（COVID-19）：小分子药物临床试验全景
Curr Top Med Chem. 2020;20(18):1577-1580. doi: 10.2174/156802662018200703154334.
10
Arguments in favour of remdesivir for treating SARS-CoV-2 infections.支持瑞德西韦治疗新型冠状病毒感染的论据。
Int J Antimicrob Agents. 2020 Apr;55(4):105933. doi: 10.1016/j.ijantimicag.2020.105933. Epub 2020 Mar 6.

引用本文的文献

1
Favipiravir Experience in COVID-19 Patients at a Tertiary Center Intensive Care Unit.三级中心重症监护病房中COVID-19患者使用法匹拉韦的经验
Sisli Etfal Hastan Tıp Bul. 2022 Jun 28;56(2):189-195. doi: 10.14744/SEMB.2021.35902. eCollection 2022.
2
Virology and Molecular Pathogenesis of Coronavirus Disease 2019: An Update.2019冠状病毒病的病毒学与分子发病机制：最新进展
Eurasian J Med. 2022 Oct;54(3):299-304. doi: 10.5152/eurasianjmed.2022.21133.
3
Perspectives from the frontline: A pharmacy department's response to the COVID-19 pandemic.从一线角度看问题：药房部门应对 COVID-19 大流行的举措。
Am J Health Syst Pharm. 2020 Aug 20;77(17):1409-1416. doi: 10.1093/ajhp/zxaa176.
4
Preparedness of pharmacists to respond to the emergency of the COVID-19 pandemic in Brazil: a comprehensive overview.巴西药剂师应对新冠疫情紧急情况的准备情况：全面概述。
Drugs Ther Perspect. 2020;36(10):455-462. doi: 10.1007/s40267-020-00761-7. Epub 2020 Jul 31.

本文引用的文献

1
Joint HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19.美国心力衰竭学会/美国心脏病学会/美国心脏协会联合声明回应关于在2019冠状病毒病中使用肾素-血管紧张素-醛固酮系统拮抗剂的担忧。
J Card Fail. 2020 May;26(5):370. doi: 10.1016/j.cardfail.2020.04.013.
2
Management of Critically Ill Adults With COVID-19.新型冠状病毒肺炎危重症成人患者的管理
JAMA. 2020 May 12;323(18):1839-1841. doi: 10.1001/jama.2020.4914.
3
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.羟氯喹和阿奇霉素治疗 COVID-19：一项开放标签非随机临床试验的结果。
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
4
Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection.藏而不露：治疗重症 COVID-19 感染患者的方法。
mBio. 2020 Mar 20;11(2):e00398-20. doi: 10.1128/mBio.00398-20.
5
COVID-19: consider cytokine storm syndromes and immunosuppression.2019冠状病毒病：考虑细胞因子风暴综合征和免疫抑制。
Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.
6
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.洛匹那韦-利托那韦治疗成人重症 COVID-19 患者的临床试验。
N Engl J Med. 2020 May 7;382(19):1787-1799. doi: 10.1056/NEJMoa2001282. Epub 2020 Mar 18.
7
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素：一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
8
Discovering drugs to treat coronavirus disease 2019 (COVID-19).发现治疗2019冠状病毒病（COVID-19）的药物。
Drug Discov Ther. 2020;14(1):58-60. doi: 10.5582/ddt.2020.01012.
9
COVID-19: a novel coronavirus and a novel challenge for critical care.新型冠状病毒肺炎：一种新型冠状病毒以及危重症护理面临的新挑战。
Intensive Care Med. 2020 May;46(5):833-836. doi: 10.1007/s00134-020-05955-1. Epub 2020 Mar 3.
10
Clinical Characteristics of Coronavirus Disease 2019 in China.《中国 2019 年冠状病毒病临床特征》
N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.